Melanie Heiss

发表

INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

Michael Platten, Annette Kopp-Schneider, Stefan M. Pfister, 2020, BMC Cancer.